Filing Details

Accession Number:
0001209191-21-024711
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-02 17:22:18
Reporting Period:
2021-04-01
Accepted Time:
2021-04-02 17:22:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1549595 Nurix Therapeutics Inc. NRIX Pharmaceutical Preparations (2834) 270838048
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1817160 Gwenn Hansen C/O Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco CA 94158
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-01 400 $7.26 14,204 No 4 M Direct
Common Stock Disposition 2021-04-01 400 $31.55 13,804 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-04-01 400 $0.00 400 $7.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
73,866 2030-02-26 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.